Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 19-Sep-24 8:02 PM View:  | Sommadossi Jean-Pierre President, CEO, and Chairman Director | Atea Pharmaceuticals, Inc. (AVIR) | 19-Sep-24 | Sale | 1,841 | $4.00 | $7,367.50 | (< 1%) 5.98M to 5.98M | |
| 19-Sep-24 8:02 PM View: | Sommadossi Jean-Pierre President, CEO, and Chairman Director | Atea Pharmaceuticals, Inc. (AVIR) | 18-Sep-24 | Sale | 22,187 | $4.03 | $89,469.10 | (< 1%) 6.01M to 5.98M | |
| 19-Sep-24 8:02 PM View: | Sommadossi Jean-Pierre President, CEO, and Chairman Director | Atea Pharmaceuticals, Inc. (AVIR) | 17-Sep-24 | Sale | 33,941 | $4.05 | $137,318.00 | (< 1%) 6.04M to 6.01M | |
| 21-Jun-24 5:59 PM View: | Polsky Bruce Director | Atea Pharmaceuticals, Inc. (AVIR) | 20-Jun-24 | Sale | 17,544 | $3.49 | $61,144.30 | (21%) 83.15K to 65.61K | |
| 18-Jun-24 5:00 PM View: | Polsky Bruce Director | Atea Pharmaceuticals, Inc. (AVIR) | 16-Jun-24 | Option Exercise | 33,150 | -- | -- | 66% 50.0K to 83.15K | |
| 18-Jun-24 5:00 PM View: | Berger Franklin M Director | Atea Pharmaceuticals, Inc. (AVIR) | 16-Jun-24 | Option Exercise | 33,150 | -- | -- | 4% 778.35K to 811.5K | |
| 18-Jun-24 5:00 PM View: | Adams Jerome M. Director | Atea Pharmaceuticals, Inc. (AVIR) | 16-Jun-24 | Option Exercise | 33,150 | -- | -- | 100% 0 to 33.15K | |
| 18-Jun-24 5:00 PM View: | Lucidi Bruno Director | Atea Pharmaceuticals, Inc. (AVIR) | 16-Jun-24 | Option Exercise | 33,150 | -- | -- | 66% 50.0K to 83.15K | |
| 18-Jun-24 5:00 PM View: | Duncan Barbara Gayle Director | Atea Pharmaceuticals, Inc. (AVIR) | 16-Jun-24 | Option Exercise | 33,150 | -- | -- | 100% 0 to 33.15K | |
| 18-Jun-24 5:00 PM View: | Murphy Polly A. Director | Atea Pharmaceuticals, Inc. (AVIR) | 16-Jun-24 | Option Exercise | 33,150 | -- | -- | 142% 23.3K to 56.45K | |
| 07-Jun-24 6:34 PM View: | Sommadossi Jean-Pierre President, CEO, and Chairman Director | Atea Pharmaceuticals, Inc. (AVIR) | 05-Jun-24 | Sale | 1,006 | $4.00 | $4,024.00 | (< 1%) 6.04M to 6.04M | |
| 02-Feb-24 9:29 PM View: | Horga Maria Arantxa Chief Medical Officer | Atea Pharmaceuticals, Inc. (AVIR) | 01-Feb-24 | Planned Option Sale | 15,870 | $3.84 | $60,963.00 | (38%) 41.53K to 25.66K | |
| 02-Feb-24 9:26 PM View: | Foster Wayne EVP, Chief Accounting Officer | Atea Pharmaceuticals, Inc. (AVIR) | 01-Feb-24 | Planned Option Sale | 12,477 | $3.84 | $47,904.20 | (37%) 33.33K to 20.86K | |
| 02-Feb-24 9:25 PM View: | Vavricka John Chief Commercial Officer | Atea Pharmaceuticals, Inc. (AVIR) | 01-Feb-24 | Planned Option Sale | 11,819 | $3.84 | $45,420.40 | (10%) 115.84K to 104.02K | |
| 02-Feb-24 9:30 PM View: | Sommadossi Jean-Pierre President, CEO, and Chairman Director | Atea Pharmaceuticals, Inc. (AVIR) | 01-Feb-24 | Planned Option Sale | 56,910 | $3.85 | $218,819.00 | (< 1%) 6.1M to 6.04M | |
| 02-Feb-24 9:24 PM View: | Hammond Janet Mj Chief Development Officer | Atea Pharmaceuticals, Inc. (AVIR) | 01-Feb-24 | Planned Option Sale | 14,029 | $3.84 | $53,913.40 | (28%) 49.39K to 35.36K | |
| 02-Feb-24 9:31 PM View: | Corcoran Andrea See Remarks | Atea Pharmaceuticals, Inc. (AVIR) | 01-Feb-24 | Planned Option Sale | 15,843 | $3.84 | $60,914.80 | (2%) 686.05K to 670.21K | |
| 02-Feb-24 9:25 PM View: | Vavricka John Chief Commercial Officer | Atea Pharmaceuticals, Inc. (AVIR) | 31-Jan-24 | Option Exercise | 33,334 | -- | -- | 40% 82.51K to 115.84K | |
| 02-Feb-24 9:30 PM View: | Sommadossi Jean-Pierre President, CEO, and Chairman Director | Atea Pharmaceuticals, Inc. (AVIR) | 31-Jan-24 | Option Exercise | 173,467 | -- | -- | 3% 5.93M to 6.1M | |
| 02-Feb-24 9:24 PM View: | Hammond Janet Mj Chief Development Officer | Atea Pharmaceuticals, Inc. (AVIR) | 31-Jan-24 | Option Exercise | 46,800 | -- | -- | 1806% 2.59K to 49.39K | |
| 02-Feb-24 9:31 PM View: | Corcoran Andrea See Remarks | Atea Pharmaceuticals, Inc. (AVIR) | 31-Jan-24 | Option Exercise | 44,367 | -- | -- | 7% 641.68K to 686.05K | |
| 02-Feb-24 9:29 PM View: | Horga Maria Arantxa Chief Medical Officer | Atea Pharmaceuticals, Inc. (AVIR) | 31-Jan-24 | Option Exercise | 41,534 | -- | -- | 100% 0 to 41.53K | |
| 02-Feb-24 9:26 PM View: | Foster Wayne EVP, Chief Accounting Officer | Atea Pharmaceuticals, Inc. (AVIR) | 31-Jan-24 | Option Exercise | 33,334 | -- | -- | 100% 0 to 33.33K | |
| 15-Nov-22 8:00 PM View: | Berger Franklin M Director | Atea Pharmaceuticals, Inc. (AVIR) | 14-Nov-22 | Sale | 16,166 | $5.16 | $83,351.90 | (2%) 794.52K to 778.35K | |
| 15-Nov-22 8:00 PM View: | Berger Franklin M Director | Atea Pharmaceuticals, Inc. (AVIR) | 11-Nov-22 | Sale | 25,500 | $5.15 | $131,333.00 | (3%) 820.02K to 794.52K | |
| 21-Dec-21 9:41 PM View: | Murphy Polly A. Director | Atea Pharmaceuticals, Inc. (AVIR) | 20-Dec-21 | Private Purchase | 12,000 | $8.57 | $102,796.00 | 106% 11.29K to 23.3K | |
| 04-Nov-20 4:05 PM View: | Rock Springs Capital Manage... 10% Owner | Atea Pharmaceuticals, Inc. (AVIR) | 03-Nov-20 | Conversion | 1,694,420 | -- | -- | 100% 0 to 1.69M | |
| 03-Nov-20 8:04 PM View: | Vavricka John Chief Commercial Officer | Atea Pharmaceuticals, Inc. (AVIR) | 03-Nov-20 | Conversion | 82,508 | -- | -- | 100% 0 to 82.51K | |
| 03-Nov-20 8:08 PM View: | Sommadossi Jean-Pierre President, CEO, and Chairman Director | Atea Pharmaceuticals, Inc. (AVIR) | 03-Nov-20 | Conversion | 750,000 | -- | -- | 14% 5.17M to 5.92M | |
| 03-Nov-20 8:05 PM View: | Chu Chung K. 10% Owner | Atea Pharmaceuticals, Inc. (AVIR) | 03-Nov-20 | Conversion | 176,862 | -- | -- | 18% 1000.0K to 1.18M | |
| 03-Nov-20 8:08 PM View: | Corcoran Andrea See Remarks | Atea Pharmaceuticals, Inc. (AVIR) | 03-Nov-20 | Conversion | 133,004 | -- | -- | 27% 500.0K to 633.0K | |
| 03-Nov-20 8:09 PM View: | Murphy Polly A. Director | Atea Pharmaceuticals, Inc. (AVIR) | 03-Nov-20 | Conversion | 11,295 | -- | -- | 100% 0 to 11.29K | |
| 03-Nov-20 8:09 PM View: | Berger Franklin M Director | Atea Pharmaceuticals, Inc. (AVIR) | 03-Nov-20 | Purchase | 41,666 | $24.00 | $999,984.00 | 5% 778.35K to 820.02K | |
| 04-Nov-20 4:05 PM View: | Rock Springs Capital Manage... 10% Owner | Atea Pharmaceuticals, Inc. (AVIR) | 03-Nov-20 | Purchase Duplicate | 250,000 | $24.00 | $6,000,000.00 | 15% 1.69M to 1.94M | |
| 03-Nov-20 9:36 PM View: | Hack Andrew A. F. Director | Atea Pharmaceuticals, Inc. (AVIR) | 03-Nov-20 | Conversion | 5,365,660 | -- | -- | 100% 0 to 5.37M | |
| 05-Nov-20 4:01 PM View: | Cormorant Asset Management,... | Atea Pharmaceuticals, Inc. (AVIR) | 03-Nov-20 | Conversion | 6,411,360 | -- | -- | 100% 0 to 6.41M | |
| 03-Nov-20 9:36 PM View: | Hack Andrew A. F. Director | Atea Pharmaceuticals, Inc. (AVIR) | 03-Nov-20 | Purchase | 250,000 | $24.00 | $6,000,000.00 | 5% 5.37M to 5.62M | |
| 03-Nov-20 8:09 PM View: | Berger Franklin M Director | Atea Pharmaceuticals, Inc. (AVIR) | 03-Nov-20 | Conversion | 759,606 | -- | -- | 4052% 18.75K to 778.35K |
